EUCTR2005-003956-37-DK进行中（未招募）1 期
Five year single-blind, phase III effectiveness randomised actively controlled clinical trial in new onset juvenile dermatomyositis: prednisone versus prednisone plus cyclosporine A versus prednisone plus methotrexate
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 132
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Newly diagnosed and untreated children (only treatment with 1 NSAID is allowed
- •and/or prednisone >1 mg/kg/day for no more than 1 month from diagnosis) with
- •probable or definite diagnosis of JDM according to the Bohan and Peter criteria (12;13).
- •If a muscle biopsy will be performed (optional) it will be read by the pathologists of the
- •participating centres (light and immunofluorescence). Slides of paraffin-embedded
- •sections from all patients will be re-viewed by a blinded myopathologist at PRINTO.
- •2) Age at enrolment = 18 years.
- •3) Female of child-bearing potential must have a negative pregnancy test at the beginning
- •of the trial, and then every 3 months. If sexually active, they must agree to use adequate
- •contraception, throughout study participation, and must have no intention of conceiving
- •during the course of the study. Post-pubertal males must have no plans to father a child
- •during the study and agree to use adequate birth control methods if sexually active.
- •4) Ability to comply with the entire study procedures, ability to communicate
- •meaningfully with the investigational staff, competence to give written informed
- •consent; to be applied to the parents and/or patients, as appropriate
- •5) Duly executed, written, informed consent obtained from the parents/patient.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) Neutrophil count <1,500/mm3 and/or platelet count <50,000/mm3
- •2) Demonstration of cutaneous or gastrointestinal ulceration of JDM related
- •pulmonary disease or cardiomyopathy at the time of diagnosis.
- •3) History of poor compliance.
- •4) Evidence of current use of alcohol or illicit drugs abuse.
- •5) Live vaccines not allowed during the entire duration of the trial.
研究者
相似试验
进行中（未招募）
1 期
Five year single-blind, phase III effectiveness randomised actively controlled clinical trial in new onset juvenile systemic lupus erythematosus nephritis: oral cyclophosphamide versus high dose intravenous cyclophosphamide versus intermediate dose intravenous cyclophosphamide - PRINTO JSLE TrialEUCTR2005-003957-28-BEniversity Hospital Gent216
进行中（未招募）
不适用
Five year single-blind, phase III effectiveness randomised actively controlled clinical trial in new onset juvenile dermatomyositis:prednisone versus prednisone plus cyclosporine A versus prednisone plus mehotrexateJuvenile Dermatomyositis at onsetEUCTR2005-003956-37-NLIstituto Giannina Gaslini160
进行中（未招募）
不适用
Five year single blind, phase III effectiveness randomised actively controlled clinical trial in new onset juvenile dermatomyositis: prednisone versus prednisone plus cyclosporine A versus prednisone plus methotrexateJuvenile Dermatomyositis at onsetEUCTR2005-003956-37-SEIstituto Giannina Gaslini132
进行中（未招募）
不适用
Five year single blind, phase III effectiveness randomised actively controlled clinical trial in new onset juvenile dermatomyositis: prednisolone versus prednisone plus cyclosporine A versus prednisone plus methotrexateJuvenile Dermatomyositis at onsetEUCTR2005-003956-37-GBIstituto Giannina Gaslini132
进行中（未招募）
不适用
Five year single blind, phase III effectiveness randomised actively controlled clinical trial in new onset juvenile dermatomyositis: prednisone versus prednisone plus cyclosporine A versus prednisone plus methotrexate - PRINTO JDM TrialJuvenile Dermatomyositis at onsetEUCTR2005-003956-37-BEniversity Hospital Gent180